Bi-Specific Antibodies Therapy Market - Global Outlook and Forecast 2021-2027

April 2021 | 100 pages | ID: B8B3955474DBEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Bi-Specific Antibodies Therapy in Global, including the following market information:

Global Bi-Specific Antibodies Therapy Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Bi-Specific Antibodies Therapy market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Bi-Specific Antibodies Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Bi-Specific Antibodies Therapy Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Bi-Specific Antibodies Therapy Market Segment Percentages, By Type, 2020 (%)

• Asymmetric Antibodies
• Symmetric Antibodies
• Fragment Antibodies

China Bi-Specific Antibodies Therapy Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Bi-Specific Antibodies Therapy Market Segment Percentages, By Application, 2020 (%)

• Colon Cancer
• Prostate Cancer
• Cervical Cancer
• Breast Cancer
• Lung Cancer
• Others

Global Bi-Specific Antibodies Therapy Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Bi-Specific Antibodies Therapy Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Bi-Specific Antibodies Therapy Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Bi-Specific Antibodies Therapy Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Amgen Inc.
• Roche
• AbbVie Inc.
• OncoMed Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Xencor, Inc.
• MacroGenics, Inc.
• Aptevo Therapeutics Inc.
• Ligand Pharmaceuticals, Inc.
• Regeneron Pharmaceuticals, Inc.
• Fresenius
• Merus

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Bi-Specific Antibodies Therapy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Bi-Specific Antibodies Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL BI-SPECIFIC ANTIBODIES THERAPY OVERALL MARKET SIZE

2.1 Global Bi-Specific Antibodies Therapy Market Size: 2021 VS 2027
2.2 Global Bi-Specific Antibodies Therapy Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Bi-Specific Antibodies Therapy Players in Global Market
3.2 Top Global Bi-Specific Antibodies Therapy Companies Ranked by Revenue
3.3 Global Bi-Specific Antibodies Therapy Revenue by Companies
3.4 Top 3 and Top 5 Bi-Specific Antibodies Therapy Companies in Global Market, by Revenue in 2020
3.5 Global Companies Bi-Specific Antibodies Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Bi-Specific Antibodies Therapy Players in Global Market
  3.6.1 List of Global Tier 1 Bi-Specific Antibodies Therapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Bi-Specific Antibodies Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Bi-Specific Antibodies Therapy Market Size Markets, 2021 & 2027
  4.1.2 Asymmetric Antibodies
  4.1.3 Symmetric Antibodies
  4.1.4 Fragment Antibodies
4.2 By Type - Global Bi-Specific Antibodies Therapy Revenue & Forecasts
  4.2.1 By Type - Global Bi-Specific Antibodies Therapy Revenue, 2016-2021
  4.2.2 By Type - Global Bi-Specific Antibodies Therapy Revenue, 2022-2027
  4.2.3 By Type - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Bi-Specific Antibodies Therapy Market Size, 2021 & 2027
  5.1.2 Colon Cancer
  5.1.3 Prostate Cancer
  5.1.4 Cervical Cancer
  5.1.5 Breast Cancer
  5.1.6 Lung Cancer
  5.1.7 Others
5.2 By Application - Global Bi-Specific Antibodies Therapy Revenue & Forecasts
  5.2.1 By Application - Global Bi-Specific Antibodies Therapy Revenue, 2016-2021
  5.2.2 By Application - Global Bi-Specific Antibodies Therapy Revenue, 2022-2027
  5.2.3 By Application - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Bi-Specific Antibodies Therapy Market Size, 2021 & 2027
6.2 By Region - Global Bi-Specific Antibodies Therapy Revenue & Forecasts
  6.2.1 By Region - Global Bi-Specific Antibodies Therapy Revenue, 2016-2021
  6.2.2 By Region - Global Bi-Specific Antibodies Therapy Revenue, 2022-2027
  6.2.3 By Region - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Bi-Specific Antibodies Therapy Revenue, 2016-2027
  6.3.2 US Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.3.3 Canada Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.3.4 Mexico Bi-Specific Antibodies Therapy Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Bi-Specific Antibodies Therapy Revenue, 2016-2027
  6.4.2 Germany Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.4.3 France Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.4.4 U.K. Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.4.5 Italy Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.4.6 Russia Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.4.7 Nordic Countries Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.4.8 Benelux Bi-Specific Antibodies Therapy Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Bi-Specific Antibodies Therapy Revenue, 2016-2027
  6.5.2 China Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.5.3 Japan Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.5.4 South Korea Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.5.5 Southeast Asia Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.5.6 India Bi-Specific Antibodies Therapy Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Bi-Specific Antibodies Therapy Revenue, 2016-2027
  6.6.2 Brazil Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.6.3 Argentina Bi-Specific Antibodies Therapy Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Bi-Specific Antibodies Therapy Revenue, 2016-2027
  6.7.2 Turkey Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.7.3 Israel Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.7.4 Saudi Arabia Bi-Specific Antibodies Therapy Market Size, 2016-2027
  6.7.5 UAE Bi-Specific Antibodies Therapy Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Amgen Inc.
  7.1.1 Amgen Inc. Corporate Summary
  7.1.2 Amgen Inc. Business Overview
  7.1.3 Amgen Inc. Bi-Specific Antibodies Therapy Major Product Offerings
  7.1.4 Amgen Inc. Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.1.5 Amgen Inc. Key News
7.2 Roche
  7.2.1 Roche Corporate Summary
  7.2.2 Roche Business Overview
  7.2.3 Roche Bi-Specific Antibodies Therapy Major Product Offerings
  7.2.4 Roche Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.2.5 Roche Key News
7.3 AbbVie Inc.
  7.3.1 AbbVie Inc. Corporate Summary
  7.3.2 AbbVie Inc. Business Overview
  7.3.3 AbbVie Inc. Bi-Specific Antibodies Therapy Major Product Offerings
  7.3.4 AbbVie Inc. Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.3.5 AbbVie Inc. Key News
7.4 OncoMed Pharmaceuticals, Inc.
  7.4.1 OncoMed Pharmaceuticals, Inc. Corporate Summary
  7.4.2 OncoMed Pharmaceuticals, Inc. Business Overview
  7.4.3 OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Major Product Offerings
  7.4.4 OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.4.5 OncoMed Pharmaceuticals, Inc. Key News
7.5 Glenmark Pharmaceuticals Limited
  7.5.1 Glenmark Pharmaceuticals Limited Corporate Summary
  7.5.2 Glenmark Pharmaceuticals Limited Business Overview
  7.5.3 Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Major Product Offerings
  7.5.4 Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.5.5 Glenmark Pharmaceuticals Limited Key News
7.6 Xencor, Inc.
  7.6.1 Xencor, Inc. Corporate Summary
  7.6.2 Xencor, Inc. Business Overview
  7.6.3 Xencor, Inc. Bi-Specific Antibodies Therapy Major Product Offerings
  7.6.4 Xencor, Inc. Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.6.5 Xencor, Inc. Key News
7.7 MacroGenics, Inc.
  7.7.1 MacroGenics, Inc. Corporate Summary
  7.7.2 MacroGenics, Inc. Business Overview
  7.7.3 MacroGenics, Inc. Bi-Specific Antibodies Therapy Major Product Offerings
  7.4.4 MacroGenics, Inc. Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.7.5 MacroGenics, Inc. Key News
7.8 Aptevo Therapeutics Inc.
  7.8.1 Aptevo Therapeutics Inc. Corporate Summary
  7.8.2 Aptevo Therapeutics Inc. Business Overview
  7.8.3 Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Major Product Offerings
  7.8.4 Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.8.5 Aptevo Therapeutics Inc. Key News
7.9 Ligand Pharmaceuticals, Inc.
  7.9.1 Ligand Pharmaceuticals, Inc. Corporate Summary
  7.9.2 Ligand Pharmaceuticals, Inc. Business Overview
  7.9.3 Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Major Product Offerings
  7.9.4 Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.9.5 Ligand Pharmaceuticals, Inc. Key News
7.10 Regeneron Pharmaceuticals, Inc.
  7.10.1 Regeneron Pharmaceuticals, Inc. Corporate Summary
  7.10.2 Regeneron Pharmaceuticals, Inc. Business Overview
  7.10.3 Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Major Product Offerings
  7.10.4 Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.10.5 Regeneron Pharmaceuticals, Inc. Key News
7.11 Fresenius
  7.11.1 Fresenius Corporate Summary
  7.11.2 Fresenius Business Overview
  7.11.3 Fresenius Bi-Specific Antibodies Therapy Major Product Offerings
  7.11.4 Fresenius Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.11.5 Fresenius Key News
7.12 Merus
  7.12.1 Merus Corporate Summary
  7.12.2 Merus Business Overview
  7.12.3 Merus Bi-Specific Antibodies Therapy Major Product Offerings
  7.12.4 Merus Bi-Specific Antibodies Therapy Revenue in Global (2016-2021)
  7.12.5 Merus Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Bi-Specific Antibodies Therapy Market Opportunities & Trends in Global Market
Table 2. Bi-Specific Antibodies Therapy Market Drivers in Global Market
Table 3. Bi-Specific Antibodies Therapy Market Restraints in Global Market
Table 4. Key Players of Bi-Specific Antibodies Therapy in Global Market
Table 5. Top Bi-Specific Antibodies Therapy Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Bi-Specific Antibodies Therapy Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Bi-Specific Antibodies Therapy Revenue Share by Companies, 2016-2021
Table 8. Global Companies Bi-Specific Antibodies Therapy Product Type
Table 9. List of Global Tier 1 Bi-Specific Antibodies Therapy Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Bi-Specific Antibodies Therapy Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Bi-Specific Antibodies Therapy Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Bi-Specific Antibodies Therapy Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Bi-Specific Antibodies Therapy Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Bi-Specific Antibodies Therapy Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Bi-Specific Antibodies Therapy Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Bi-Specific Antibodies Therapy Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022-2027
Table 30. Amgen Inc. Corporate Summary
Table 31. Amgen Inc. Bi-Specific Antibodies Therapy Product Offerings
Table 32. Amgen Inc. Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 33. Roche Corporate Summary
Table 34. Roche Bi-Specific Antibodies Therapy Product Offerings
Table 35. Roche Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 36. AbbVie Inc. Corporate Summary
Table 37. AbbVie Inc. Bi-Specific Antibodies Therapy Product Offerings
Table 38. AbbVie Inc. Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 39. OncoMed Pharmaceuticals, Inc. Corporate Summary
Table 40. OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Product Offerings
Table 41. OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 42. Glenmark Pharmaceuticals Limited Corporate Summary
Table 43. Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Product Offerings
Table 44. Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 45. Xencor, Inc. Corporate Summary
Table 46. Xencor, Inc. Bi-Specific Antibodies Therapy Product Offerings
Table 47. Xencor, Inc. Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 48. MacroGenics, Inc. Corporate Summary
Table 49. MacroGenics, Inc. Bi-Specific Antibodies Therapy Product Offerings
Table 50. MacroGenics, Inc. Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 51. Aptevo Therapeutics Inc. Corporate Summary
Table 52. Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Product Offerings
Table 53. Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 54. Ligand Pharmaceuticals, Inc. Corporate Summary
Table 55. Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Product Offerings
Table 56. Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 57. Regeneron Pharmaceuticals, Inc. Corporate Summary
Table 58. Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Product Offerings
Table 59. Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 60. Fresenius Corporate Summary
Table 61. Fresenius Bi-Specific Antibodies Therapy Product Offerings
Table 62. Fresenius Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)
Table 63. Merus Corporate Summary
Table 64. Merus Bi-Specific Antibodies Therapy Product Offerings
Table 65. Merus Bi-Specific Antibodies Therapy Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Bi-Specific Antibodies Therapy Segment by Type
Figure 2. Bi-Specific Antibodies Therapy Segment by Application
Figure 3. Global Bi-Specific Antibodies Therapy Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Bi-Specific Antibodies Therapy Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Bi-Specific Antibodies Therapy Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Bi-Specific Antibodies Therapy Revenue in 2020
Figure 8. By Type - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 9. By Application - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 10. By Region - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 11. By Country - North America Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 12. US Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 16. Germany Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 17. France Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 24. China Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 28. India Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 30. Brazil Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 33. Turkey Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2016-2027
Figure 37. Amgen Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Roche Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. AbbVie Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. OncoMed Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Glenmark Pharmaceuticals Limited Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Xencor, Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. MacroGenics, Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Aptevo Therapeutics Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Ligand Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Regeneron Pharmaceuticals, Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Fresenius Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)